According to some Internet users, the WHO announced that receiving the vaccine against monkeypox would be like taking part in a clinical trial.
- Over 2,000 cases of monkeypox have been detected worldwide.
- The outbreak has been classified as an international emergency by the WHO.
It is a video that has sown doubt.
At a press conferenceWHO Global Infectious Hazard Preparedness Unit Chief Tim Nguyen is quoted as saying: “I would like to underline one thing which is very important for the WHO. We have uncertainty about the effectiveness of these vaccines because they have not been used in this setting and on this scale before.“
Uncertainties
After a cut that can be seen in the video, he continues: “When these vaccines are in development, they are delivered in clinical trial studies and the prospective collection of these data to increase our understanding of the effectiveness of these vaccines..”
These statements made internet users react strongly on twitter as the newspaper tells 20 minutes: “We are free guinea pigs for them“said one netizen.”The government fails to tell us that these bites are not reliable by asking us to get bitten!!“, argues another.
But that’s a bad shortcut. Indeed, on behalf of the WHO, Tim Nguyen evokes the phase of development and collection of data collected during vaccinations which make it possible to monitor the effects and evolutions of the products. The same was true for vaccines against Covid-19 which had provoked similar debates when they were marketed.
Authorized vaccine
The European Medicines Agency (EMA) is indeed very clear:There is an authorized monkeypox vaccine in the EU, Imvanex, and it is not an experimental vaccineIndeed, the Imvanex vaccine is licensed to protect adults against monkeypox (Monkeypox) and is marketed as Jynneos in the United States.
Once a drug has been granted marketing authorization by a regulatory authority, it can no longer be considered an investigational product, said the government vaccine information site last February. Or, “dSince July 25, 2022, the Imvanex vaccine has obtained European marketing authorization (MA) for the indication of active immunization against Monkeypox in adults. says the news site today.
Currently, an experiment is underway as part of the ramp-up of vaccination against the monkey virus. A decree published in the official journal of August 8 allows five pharmacies in France to prescribe and administer a vaccine against monkeypox since August 10, for two weeks.
